title: Targeted lymph node immunization can protect cats from a mucosal challenge with feline immunodeficiency virus.
abstract: With the rapid spread of human immunodeficiency virus (HIV) infection worldwide it is clear that effective strategies for mucosal vaccination against lentiviruses are urgently required. The aim of the present study is to determine whether protective immune responses against a mucosal challenge by feline immunodeficiency virus (FIV) can be elicited by targeting the immunization to the medial iliac lymph nodes--the principal site of migration of cells from the genital and rectal mucosa. Cats were challenged with homologous FIV via the rectal route. Targeted lymph node immunization was found to be an effective route of immunization eliciting both humoral and proliferative responses to peptide-based and fixed cell vaccines. Vaccination with fixed virus infected cells elicited protection against a cell-free mucosal FIV challenge. In addition, some cats vaccinated with fixed uninfected cells also remained uninfected following a cell-associated FIV challenge.
authors.affiliation: Department of Clinical Veterinary Science, University of Bristol, Langford, BS40 5DU, Bristol, UK. sue.finesrty@bristol.ac.uk
authors.forename: S
authors.initials: S
authors.lastname: Finerty
authors.forename: C R
authors.initials: CR
authors.lastname: Stokes
authors.forename: T J
authors.initials: TJ
authors.lastname: Gruffydd-Jones
authors.forename: T J
authors.initials: TJ
authors.lastname: Hillman
authors.forename: F J
authors.initials: FJ
authors.lastname: Barr
authors.forename: D A
authors.initials: DA
authors.lastname: Harbour
mesh_terms: D000285:Administration, Rectal; D000595:Amino Acid Sequence; D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis / Q000276:immunology; D000956:Antigens, Viral / Q000008:administration & dosage* / Q000737:chemistry / Q000276:immunology; D002415:Cats; D002478:Cells, Cultured / Q000637:transplantation / Q000821:virology; D004341:Drug Evaluation; D016181:Feline Acquired Immunodeficiency Syndrome / Q000276:immunology / Q000517:prevention & control*; D015683:Gene Products, gag / Q000276:immunology; D006023:Glycoproteins / Q000008:administration & dosage* / Q000737:chemistry / Q000276:immunology; D016089:Immunodeficiency Virus, Feline / Q000276:immunology* / Q000502:physiology; D007272:Injections, Intralymphatic; D008198:Lymph Nodes / Q000276:immunology*; D008969:Molecular Sequence Data; D010446:Peptide Fragments / Q000008:administration & dosage / Q000737:chemistry / Q000276:immunology; D010865:Pilot Projects; D013601:T-Lymphocytes / Q000637:transplantation / Q000821:virology; D014611:Vaccination / Q000379:methods / Q000662:veterinary*; D022223:Vaccines, Subunit / Q000008:administration & dosage / Q000276:immunology; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology; D014759:Viral Envelope Proteins / Q000008:administration & dosage* / Q000737:chemistry / Q000276:immunology; D014765:Viral Vaccines / Q000008:administration & dosage* / Q000276:immunology
chemical_list: D000914:Antibodies, Viral; D000956:Antigens, Viral; D015683:Gene Products, gag; D006023:Glycoproteins; D010446:Peptide Fragments; D022223:Vaccines, Subunit; D014614:Vaccines, Synthetic; D014759:Viral Envelope Proteins; D014765:Viral Vaccines; C445079:envelope protein, Feline immunodeficiency virus; C074662:p24 protein, Feline immunodeficiency virus